SANES

10.406

-0.22%↓

BBVA

18.78

-0.9%↓

CABK

10.752

-0.55%↓

INGA

25.7

+0.71%↑

NDA.FI

15.62

+0.32%↑

SANES

10.406

-0.22%↓

BBVA

18.78

-0.9%↓

CABK

10.752

-0.55%↓

INGA

25.7

+0.71%↑

NDA.FI

15.62

+0.32%↑

SANES

10.406

-0.22%↓

BBVA

18.78

-0.9%↓

CABK

10.752

-0.55%↓

INGA

25.7

+0.71%↑

NDA.FI

15.62

+0.32%↑

SANES

10.406

-0.22%↓

BBVA

18.78

-0.9%↓

CABK

10.752

-0.55%↓

INGA

25.7

+0.71%↑

NDA.FI

15.62

+0.32%↑

SANES

10.406

-0.22%↓

BBVA

18.78

-0.9%↓

CABK

10.752

-0.55%↓

INGA

25.7

+0.71%↑

NDA.FI

15.62

+0.32%↑

Home・Lista de Ações・Bayer AG

Bayer AG

Fechado

SetorFinanças

38.84 5.13

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

36.73

Máximo

37.38

Indicadores-chave
By Trading Economics
Rendimento	-2.8B -3.8B
Vendas	1.8B 11B
EPS	-3.82
Rendimento de Dividendos	0.29
Margem de lucro	-32.847
Funcionários	87,280
EBITDA	1.4B 2B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+29.31% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	0.29% 4.62%
Próximos Ganhos	12 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-3.2B 37B
Abertura anterior	33.71
Fecho anterior	38.84

Sentimento de Notícias

By Acuity

34%

66%

106 / 439 Ranking em Finance

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

22.99 / 23.88 Suporte e Resistência

Bayer AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de mai. de 2026, 10:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6 de mai. de 2026, 07:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

4 de mar. de 2026, 11:06 UTC

Ganhos

Bayer Net Loss Widens on Weedkiller Litigation Charges -- 2nd Update

4 de mar. de 2026, 07:45 UTC

Ganhos

Bayer Net Loss Widens on Weedkiller Litigation Charges -- Update

4 de mar. de 2026, 07:09 UTC

Ganhos

Bayer Net Loss Widens on Weedkiller Litigation Charges

6 de mai. de 2026, 06:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6 de mai. de 2026, 06:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6 de mai. de 2026, 06:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6 de mai. de 2026, 06:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Pay $300M Upfront

6 de mai. de 2026, 06:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

6 de mai. de 2026, 06:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer to Buy Perfuse Therapeutics

6 de mai. de 2026, 06:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer To Acquire Perfuse Therapeutics To Complement Ophthalmology Pipeline >BAYN.XE

8 de abr. de 2026, 14:41 UTC

Ganhos

Buy Johnson & Johnson Stock Ahead of Earnings, Analyst Says. The Gains Can Continue. -- Barrons.com

1 de abr. de 2026, 14:24 UTC

Conversa de Mercado

Bayer Pharma Head Touts Healthiest Pipeline in Company's History -- Market Talk

16 de mar. de 2026, 14:28 UTC

Conversa de Mercado

Bayer Edging Closer to Litigation Resolution -- Market Talk

5 de mar. de 2026, 07:03 UTC

Conversa de Mercado

Bayer's Roundup Settlement Isn't a Done Deal Yet -- Market Talk

4 de mar. de 2026, 12:52 UTC

Conversa de Mercado

Ganhos

Bayer Sees Pharma Business Turning a Corner -- Market Talk

4 de mar. de 2026, 12:41 UTC

Conversa de Mercado

Bayer Expects Consumer Sales to Remain Under Pressure in U.S., China -- Market Talk

4 de mar. de 2026, 12:13 UTC

Conversa de Mercado

Bayer Expects Challenging Agriculture Market in 2026 -- Market Talk

4 de mar. de 2026, 10:18 UTC

Ações em Alta

Stocks to Watch Wednesday: CrowdStrike, Gitlab, Moderna, Strategy, Coinbase -- WSJ

4 de mar. de 2026, 08:32 UTC

Conversa de Mercado

Ganhos

Bayer Beats Expectations, But Currency Headwinds Cloud Outlook -- Market Talk

4 de mar. de 2026, 06:41 UTC

Ganhos

Bayer: Paul Achleitner and Colleen Goggins Won't Stand for Re-election at 2026 AGM

4 de mar. de 2026, 06:41 UTC

Ganhos

Bayer Proposes Marcel Smits and Alfred Stern as Supervisory Board Members

4 de mar. de 2026, 06:40 UTC

Ganhos

Bayer Proposes Two New Candidates for Supervisory Board

4 de mar. de 2026, 06:40 UTC

Ganhos

Bayer: 2026-End Net Debt Expected at EUR32B to EUR33B

4 de mar. de 2026, 06:39 UTC

Ganhos

Bayer Sees 2026 Free Cash Outflow of EUR1.5B-EUR2.5B Due to Litigation Payouts

4 de mar. de 2026, 06:39 UTC

Ganhos

Bayer: 2025 Core EPS Would Have Been EUR4.57 Under New Methodology

4 de mar. de 2026, 06:38 UTC

Ganhos

Bayer: Changing the Way it Calculates Core EPS

4 de mar. de 2026, 06:38 UTC

Ganhos

Bayer Sees 2026 Core EPS at EUR4.30-EUR4.80

4 de mar. de 2026, 06:37 UTC

Ganhos

Bayer Sees 2026 Ebitda Before Special Items of EUR9.6B to EUR10.1B

Comparação entre Pares

Variação de preço

Bayer AG Previsão

Preço-alvo

By TipRanks

29.31% parte superior

Previsão para 12 meses

Média 47.82 EUR 29.31%

Máximo 56 EUR

Mínimo 25 EUR

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Bayer AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para Bayer AG - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

22.99 / 23.88Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentimento

By Acuity

106 / 439 Ranking em Finanças

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.